// App-Quantinova.ai

: Long-Term Clinical Outcomes and Correlative Efficacy Analyses in Patients (Pts) with Relapsed/Refractory Follicular Lymphoma (r/r FL) Treated with Tisagenlecleucel in the Elara Trial

Researchers

Presenter

  • Martin Dreyling

Principal Investigators

  • Joaquin Martinez Lopez

  • Arne Kolstad

  • Jason P Butler

  • Monalisa Ghosh

  • Leslie L. Popplewell

  • Julio Chavez

  • Emmanuel Bachy

  • Koji Kato

  • Hideo Harigae

  • Marie Jose Kersten

  • Charalambos Andreadis

  • Peter A. Riedell

  • Phoebe Joy Ho

  • Jose A. Perez-Simon

  • Andy Chen

  • Loretta J. Nastoupil

  • Bastian von Tresckow

  • Andres J M Ferreri

  • Takanori Teshima

  • Piers E.M. Patten

  • Joseph P. McGuirk

  • Andreas Petzer

  • Fritz Offner

  • Andreas Viardot

  • Pier Luigi Zinzani

  • Ram Malladi

  • Ines Paule

  • Aiesha Zia

  • Rakesh Awasthi

  • Xia Han

  • Davide Germano

  • Darragh O'Donovan

  • Roberto Ramos

  • Aisha Masood

  • Catherine Thieblemont

  • Nathan H. Fowler

  • Stephen J. Schuster

Medical Centers

  • Department of Hematology, Hospices Civils de Lyon, Lyon Sud University Hospital, Pierre Benite, France

  • Department of Hematology/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA

  • Department of Hematology, Hokkaido University Hospital, Sapporo, Japan

  • Department of Haematology, King's College Hospital, London, United Kingdom

  • Moffitt Cancer Center, University of South Florida, Tampa, FL

  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA

  • Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

  • Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Australia

  • Oregon Health and Science University, Portland, OR

  • Royal Prince Alfred Hospital and University of Sydney, Camperdown, Sydney, Australia

  • UZ Gent, Gent, Belgium

  • Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan

  • Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy

  • University of Amsterdam, Amsterdam UMC, Amsterdam, Netherlands

  • Michigan Medicine University of Michigan, Ann Arbor, MI

  • Hospital De Octubre, Complutense University, CNIO, Madrid, Spain

  • Medizinische Klinik III, LMU Klinikum, Munich, Germany

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany

  • Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS

  • The University of Texas MD Anderson Cancer Center, Houston, TX

  • Tohoku University Hospital, Sendai, Japan

  • The University of Chicago Comprehensive Cancer Center, Chicago, IL

  • Novartis Institutes for BioMedical Research, East Hanover, NJ

  • Instituto de Biomedicina de Sevilla (IBiS), UGC-Hematología, Hospital Universitario Virgen del Rocío/ CSIC/ CIBERONC, Universidad de Sevilla, Sevilla, Spain

  • Department of Haematology and BMT, Royal Brisbane and Women's Hospital, Brisbane, Australia

  • Comprehensive Cancer Centre, King's College London, London, United Kingdom

  • On behalf of the Lunenburg Lymphoma Phase I/II Consortium-HOVON/LLPC, Amsterdam, Netherlands, Amsterdam, Netherlands

  • Hopital Saint-Louis, Paris, France

  • Lymphoma Unit, Dept of Onco-hematology, IRCCS San Raffaele Scientific Institute, Milano, Italy

  • Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway

  • Department I of Internal Medicine, West German Cancer Center Essen, Essen, Germany

Locations

  • France

  • Spain

  • United Kingdom

  • Australia

  • United States

  • Ireland

  • Germany

  • Belgium

  • Japan

  • Netherlands

  • Italy

  • Switzerland

  • Austria

  • Norway

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Follicular lymphoma

Biomarkers

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • tisagenlecleucel-t

Outcome

  • N/A

Study Design

  • Efficacy

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved